etoposide oral

The combination of pyrotinib with metronomic oral etoposide has achieved promising clinical benefits in heavily pretreated HER2-positive MBC, with acceptable and manageable toxicity.

P2, N=44, Recruiting, Beijing Sanbo Brain Hospital | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025

Niraparib combined with etoposide showed evidence of antitumor activity in platinum resistant/refractory ovarian cancer after ≤2 lines of platinum based chemotherapy, particularly in patients with a BRCA mutation, homologous recombination deficiency, or primary platinum resistance. This once-a-day oral combination was a convenient option.

P2, N=60, Not yet recruiting, shanghai pulmonary hospital; shanghai pulmonary hospital

Oral carcinoma cell line SCC25 was cultured in complete DMEM/F12 media and treated with 5μM of Etoposide (Topoisomerase II inhibitor) for 48h...These results indicate that inhibition of TOP2A is more efficacious by decreasing the mitochondrial metabolic reprogramming and thereby downregulating the key anti-apoptotic and pro-survival mediators. Thus, TOP2A represents an ideal therapeutic target and offers a potential treatment strategy for OSCC.

P1/2, N=40, Not yet recruiting, Assistance Publique Hopitaux De Marseille

P2, N=60, Not yet recruiting, Shanghai Pulmonary Hospital, Shanghai, China

P2, N=93, Not yet recruiting, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

P2, N=18, Completed, University of Cologne | Recruiting --> Completed | N=26 --> 18 | Trial completion date: Dec 2023 --> Jun 2023 | Trial primary completion date: Dec 2023 --> Jun 2023

P1, N=20, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024

To the best of our knowledge, the present case is the first of its kind to describe the synchronous double cancer, consisting of primary SCLC and IDC.

P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=66, Recruiting, Institut Curie | Active, not recruiting --> Recruiting

P2, N=66, Active, not recruiting, Institut Curie | Not yet recruiting --> Active, not recruiting

Cytoreduction therapy, including hydroxycarbamide, anthracyclines and cytarabine during induction therapy was administrated based on the 2018 Chinese APL guidelines. In summary, the present study indicated that cytoreductive chemotherapy had a dual effect of both cytoreduction and prevention of relapse in low-risk APL. Oral etoposide as cytoreduction therapy combined with oral ATRA plus RIF is expected to be a regimen with low relapse, good tolerance and great convenience. A prospective, randomized, controlled, interventional study on oral etoposide versus intravenous daunorubicin for cytoreductive chemotherapy in induction therapy in patients with low-risk APL is now going on (NCT05832320).

A current therapy option for advanced OC patients is debulking surgery; followed by platinum-based chemotherapy ± bevacizumab; followed by maintenance therapy with bevacizumab or monotherapy with PARP inhibitors. Primary endpoint is progressionfree survival (PFS). Current Trial Status: Trial in progress: there are no available results at the time of submission, and there are no available conclusions at the time of submission.

P2, N=66, Not yet recruiting, Institut Curie | Trial primary completion date: Apr 2026 --> Nov 2026

Younger patients and those with oligodendrogliomas were more likely to benefit. We consider VP16 at 50 mg/day po a valid option for patients whose performance status would allow trying an additional line of palliative systemic treatment.

Serum specimens were obtained from participants in a randomized trial evaluating the value of adding oral etoposide chemotherapy to ART in treatment-naïve people with limited-stage AIDS-KS in resource-limited settings...Early KS progression was associated with elevated pre-treatment levels of inflammation-associated biomarkers and increasing levels post-treatment. Quantifying serum biomarkers, especially CRP, may help identify persons with AIDS-KS who would benefit from early introduction of chemotherapy in addition to ART.

P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial primary completion date: Jun 2023 --> Dec 2023

The oral MCT constituted etoposide, cyclophosphamide, and tamoxifen...Oral MCT was found to be an effective and well-tolerated regime with good symptomatic control and low-moderate toxicity profile in patients with relapsed and metastatic ovarian cancer. However, 22% of patients showed grade-III/IV thrombocytopenia.

HSC4 cells were found to be more sensitive to the inhibitory effect of these drugs compared to SCC9 cells. These findings suggest that the use of Rh-C as a complementary therapy with 5-FU may have the potential for the treatment of oral cancer. the underlying mechanisms responsible for this difference in sensitivity between the two cell lines need to be further investigated.

P2, N=66, Not yet recruiting, Institut Curie

P2/3, N=600, Active, not recruiting, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Phase classification: P3 --> P2/3

P3, N=600, Active, not recruiting, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Phase classification: P2 --> P3

Apatinib combined with oral etoposide was feasible in pretreated advanced TNBC, and was easy to administer.

Adverse events of grade 3 or higher occurred in 42 (33.6%) patients in the ESA arm and 81 (65.9%) in the MESA arm. ESA with sandwiched radiotherapy is an effective, low toxicity, non-intravenous regimen with an outpatient design, and can be considered as a first-line treatment option in newly diagnosed early-stage nasal NKTCL.

P2, N=64, Recruiting, Nabil Adra | Trial completion date: Dec 2026 --> Dec 2025

P2, N=600, Active, not recruiting, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Phase classification: P3 --> P2

P1, N=20, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Dec 2023

In each case, experts would combine conventional multimodal treatment concepts, including re-irradiation, with targeted therapy based on molecular genetic findings. International cooperative trials combining a (chemo-)therapy backbone with targeted therapy approaches for defined subgroups may help to gain valid clinical data and improve treatment in pediatric patients with recurrent/progressing HGG.

Pts who received prior anti-leukemic therapies (except hydroxyurea, oral etoposide) or who had concurrent malignancies were excluded. Pts receiving 1L therapy were divided into 3 cohorts: hypomethylating agents (HMA; azacitidine/decitabine) and venetoclax (Cohort A), intensive chemotherapy (Cohort B), or HMA without venetoclax (Cohort C)...Younger age, fewer comorbidities, and higher number of pts receiving allo-SCT could have influenced apparent longer OS in the intensive chemotherapy cohort that was no longer significant in an adjusted model. Despite recent advances, TP53m AML pts continue to experience poor outcomes highlighting the significant unmet medical need and the need for novel therapies.

P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Jun 2023

Our analysis suggests a favorable efficacy and toxicity profile for VP16-T in patients with heavily pretreated HER2+ MBC.

P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Jun 2022

P1, N=20, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022

P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2022 --> Dec 2021 | Trial primary completion date: Jun 2022 --> Dec 2021

The cases highlighted the importance of rebiopsy that identified pathologically SCLC transformation after EGFR-TKI resistance, and suggested the treatment of erlotinib plus EP followed by etoposide, which could provide a reference for such phenotype.

P1, N=20, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021

 The favorable clinical benefit, good tolerance and low cost suggest that T-VP16 is a relevant option for patients with heavily pretreated HER2-positive MBC. TOP2A and HER2 co-amplification data will be presented at the meeting.